Evidence map›Paper›PMID 39821282›Full record

ArticleJournal of the National Cancer Institute2025

Mortality after cancer diagnosis among children with congenital heart disease in Denmark and Sweden.

Christina-Evmorfia Kampitsi, Line Kenborg, Hanna Mogensen, Olof Broberg, Ingrid Glimelius, Friederike Erdmann, Jeanette Falck Winther, Maria Feychting, Giorgio Tettamanti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Christina-Evmorfia KampitsiUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.ORCID 0000-0002-3907-4360
Line KenborgChildhood Cancer Research Group, Danish Cancer Institute, 2100 Copenhagen, Denmark.ORCID 0000-0002-3584-6570
Hanna MogensenUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.ORCID 0000-0001-5195-8065
Olof BrobergDepartment of Pediatric Cardiology, Skane University Hospital, 221 85 Lund, Sweden.ORCID 0000-0002-1566-5780
Ingrid GlimeliusDepartment of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0001-6158-3041
Friederike ErdmannResearch group Aetiology and Inequalities in Childhood Cancer, Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany.ORCID 0000-0002-9982-3300
Jeanette Falck WintherChildhood Cancer Research Group, Danish Cancer Institute, 2100 Copenhagen, Denmark.ORCID 0000-0002-3440-5108
Maria FeychtingUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.ORCID 0000-0002-5101-0060
Giorgio TettamantiUnit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.ORCID 0000-0002-5210-7219

Funding

Danish Childhood Cancer FoundationFORTESwedish Cancer SocietySwedish Childhood Cancer FundSwedish Research Council
6 · The paper itself

Abstract

backgroundRecent decades have witnessed tangible improvements in childhood cancer survival. However, the prognosis for children with congenital heart disease (CHD), the most prevalent birth defect, remains unclear. Due to improved survival of CHD and childhood cancer, evaluating outcomes within this intersection is important for clinical practice. We aimed to assess mortality post-cancer diagnosis among children with CHD.

methodsWe conducted a study on the population of Denmark and Sweden, born 1970-2014, with a cancer diagnosis before age 20 in the national cancer registers (end of follow-up 2015; n = 20 665). CHD diagnoses (n = 397) and recorded deaths were retrieved from national health registers. We evaluated the effect of CHD on 5-year mortality post-cancer diagnosis fitting Cox proportional hazards regression.

resultsWhen excluding children with Down syndrome, children with CHD had a higher 5-year mortality post-cancer diagnosis compared to children without (hazard ratio [HR] 1.48, 95% confidence interval [CI] = 1.18 to 1.86). This was particularly notable in children with lymphoma (HR = 2.17, 95% CI = 1.11 to 4.25) and neuroblastoma (HR = 2.39, 95% CI = 1.11 to 5.15). In more recent decades (post-1990), children with CHD had similar 5-year mortality as their counterparts without, except for children diagnosed with lymphoma, where mortality remained elevated (HR = 3.37, 95% CI = 1.65 to 6.89).

conclusionsIn this large, register-based cohort study, children with CHD fared worse post-cancer diagnosis-particularly lymphoma and neuroblastoma. While a more positive trend emerged in recent years, lymphoma-related mortality remained disproportionately high among children with CHD, underscoring the need for continued research and interventions to improve outcomes for this vulnerable group.

Indexed as

Heart Defects, CongenitalNeoplasmsAdolescentChildChild, PreschoolDenmarkFemaleHumansInfantInfant, NewbornMalePrognosisProportional Hazards ModelsRegistriesSwedenYoung Adult

Identifiers

PMID39821282
PMCPMC12145920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.